Leukotrienes in Asthma
- 145 Downloads
One of the major reasons for pursuing the chemical structure of the biological material known as slow-reacting substance of anaphylaxis (SRS-A) was that this material was known to be a potent bronchoconstrictor substance in guinea pigs  and in isolated human airways . Thirty years ago, the simple concept was that SRS-A was released from sensitized cells following antigen sensitization and challenge, and that the released material transduced a signal at an as yet to be identified receptor leading to smooth muscle constriction and therefore the manifestations of human asthmA. It has been almost 25 years since the elucidation of the structure of SRS-A as a mixture of the cysteinyl leukotrienes (LT)  and just over 5 years since agents that act on leukotriene pathway have been available as asthma treatments [4,5]. What have we learned about asthma from the use of these agents and what is the role of these agents in the treatment of asthma?
KeywordsFluticasone Propionate Asthma Treatment Moderate Asthma Late Asthmatic Response Late Asthmatic Reaction
Unable to display preview. Download preview PDF.
- 2.Brocklehurst WE. The release of histamine and the formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol (Lond) 1960; 151:416–435.Google Scholar
- 4.Obyrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127(6):472–480.Google Scholar
- 9.Hammarstrom S, Orning L, Bernstrom K. Metabolism and excretion of cysteinyl-leukotrienes. Adv Prost Thromb Leukot Res 1986; 16:383–396.Google Scholar
- 12.Asano K, Lilly CM, Odonnell WJ, Israel E, Fischer A, Ransil BJ et al. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthmA. J Allergy Clin Immunol 1995; 96(5 Part 1):643–651.Google Scholar
- 19.Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT1 antagonist, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:1–6.Google Scholar
- 21.Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Amer J Respir Crit Care Med 1999; 160(6):1862–1868.Google Scholar
- 23.Virchow JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Amer J Respir Crit Care Med 162, 578–585. 2000. Ref Type: Journal (Full)Google Scholar
- 25.Bel EH, Desmet M, Rossing TH, Timmers MC, Dijkman JH, Sterk PJ. The effect of a specific oral PAF-antagonist, MK-287, on antigen-induced early and late asthmatic reactions in man. American Review Respiratory Disease 143, A811. 1991. Ref Type: AbstractGoogle Scholar
- 28.Leckie MJ, ten Brincke A, khan j, Diamant Z, O’Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000; (In Press).Google Scholar